The effect of bisphosphonates on disease activity and bone status in ankylosing spondylitis

Trial Profile

The effect of bisphosphonates on disease activity and bone status in ankylosing spondylitis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Alendronic acid (Primary) ; Risedronic acid
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms BIAS
  • Most Recent Events

    • 19 Jul 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top